Rockville, May 03, 2023 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global grand mal seizure treatment market is valued at US$ 2 billion in 2023 and is projected to reach US$ 3.2 billion by 2033.
The grand mal seizure treatment market is expected to be driven by the increasing prevalence of epilepsy and other neurological disorders, as well as advancements in medical technologies and research related to seizures.
Antiepileptic drugs (AEDs) are the primary treatment option for grand mal seizures. There are several different types of drugs available for seizure treatment.
For more insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8547
| Grand Mal Seizure Treatment Market Scope | |
| Report Coverage | Details |
| Base year | 2022 |
| Historic period | 2017-2021 |
| Forecast period | 2023-2033 |
| Growth momentum & CAGR | Accelerate at a CAGR of 4.5% |
| Market growth 2023-2033 | US$ 3.2 Billion |
| Regional analysis | North America, Europe, APAC, South America, and Middle East and Africa |
| Key countries | US, Canada, UK, France, and Germany |
| Competitive landscape | Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
| Key companies profiled | Pfizer, Johnson & Johnson, UCB Celltech, Abbott Laboratories, GlaxoSmithKline, Novartis, Sanofi, Takeda, Teva Pharmaceutical, Shire Pharmaceuticals Limited |
| Market dynamics | Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Grand mal seizures, also known as generalized tonic-clonic seizures, are characterized by sudden and intense convulsions that affect the entire body and can cause loss of consciousness.
- According to the National Center for Biotechnology Information, around 12 million people in India are living with epilepsy, making it the country with a large of people affected by the condition.
- This condition is often associated with epilepsy, a neurological disorder that affects approximately 50 million people worldwide, according to the World Health Organization.
Healthcare providers are increasingly seeking treatment options that can effectively control seizures and minimize the risk of side effects. This has led to the development of newer AEDs and other medications that are more effective and better tolerated than traditional treatments. Wearable devices are also set to aid in the treatment of the condition in a big way.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=8547
Key Takeaways from Market Study
- Sales of grand mal seizure treatment solutions are expected to increase at a CAGR of 4.5% from 2023 to 2033.
- The global grand mal seizure treatment market is forecasted to reach US$ 3.2 billion by the end of 2033.
- North America holds a leading share of the global market due to the high prevalence of epilepsy and the presence of key market players in the region.
- The European market is progressing rapidly due to the presence of well-established healthcare facilities and rising medical tourism in the region.
Grand mal seizure treatment market increasing in prominence with the introduction of advanced wearable technologies that can gather advanced information regarding seizure attacks, says a Fact.MR analyst.
Recent Market Developments
Top companies in the grand mal seizure treatment market are making significant investments in R&D operations to develop novel and cutting-edge grand mal seizure medications. This improves their competitive position and accelerates the growth of their revenue.
- The United States Food and Drug Administration granted Lupin's abbreviated new drug application (ANDA) for Vigabatrin approval in March 2022. It is an anti-epileptic medication and is sold as a 500 mg oral solution USP.
- The medicine Ztalmy from Marinus Pharmaceuticals was authorised by the United States Food and Drug Administration in March 2022 to treat seizures in people with CDKL5 deficiency, a genetic form of epilepsy.
Key Segments of Grand Mal Seizure Treatment Industry Research
- By Drug Generation:
- First
- Second
- Third
- By Drug Class:
- Barbiturates
- Hydantoin
- Phenyltriazine
- Iminostilbenes
- Benzodiazepines
- Aliphatic Carboxylic Acids
- By Diagnosis:
- Magnetic Resonance Imaging
- Electroencephalogram
- Blood Tests
- Computed Tomography
- By End User:
- Hospitals
- Clinics
- Academic and Research Centers
For in-depth competitive analysis, Buy Now:
https://www.factmr.com/checkout/8547
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global grand mal seizure treatment market, presenting historical demand data (2018 to 2022) and forecast statistics for the period (2023 to 2033).
The study divulges essential insights on the market based on drug generation (first, second, third), drug class (barbiturates, hydantoin, phenyltriazine, iminostilbenes, benzodiazepines, aliphatic carboxylic acids), diagnosis (magnetic resonance imaging, electroencephalogram, blood tests, computed tomography), and end user (hospitals, clinics, academic and research centers), across five major regions of the world.
Key Questions Covered in the Grand Mal Seizure Treatment Market Report
- What will be the estimated size of the Market in 2023?
- At what rate will the global Grand Mal Seizure Treatment sales grow until 2033?
- Which are the factors hampering the Grand Mal Seizure Treatment demand?
- Which region will spearhead the growth in the global industry during 2023-2033?
- Which are the factors driving sales in the Grand Mal Seizure Treatment Market during the forecast period?
Check out more related studies published by Fact.MR Research:
Psychotic Disorder Treatment Market Size: At present, the global psychotic disorder treatment market size accounts for US$ 13.6 billion and is projected to surge past a valuation of US$ 24.5 billion by the end of 2032.
Hemorrhoids Treatment Devices Market Sales: One major problem leading to low sales of hemorrhoids treatment devices in some countries is the ignorance of people towards the problem. This may happen due to the awkwardness that comes with the problem.
Arterial Blood Sampling Systems Market Demand: The continuously increasing cases of accidents and trauma as well as the huge demand for blood donations and blood components for diagnostic testing are driving the arterial blood sampling systems market demand.
Pediatric HIV Infection Treatment Market Growth: Unavailability of treatment options in the underdeveloped countries can be the factor which can hamper the growth of global pediatric HIV infection treatment market. Moreover, the limited number of treatment options with a very high cost of branded drugs in various regions have impeded the growth of the global pediatric HIV.
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Connect to Author: Mr. Shambhu Nath Jha
Email : shambhu@factmr.com
Sales Team : sales@factmr.com
Follow Us: LinkedIn | Twitter | YouTube
